Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 6/20 | 0.70 |
| ▸ | LMNA | P02545 | 2/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.57 |
| ▸ | ACHE | P22303 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | CES2 | O00748 | 1/20 | 0.53 |
| ▸ | CES1 | P23141 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.50 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL85551 | 1.00 | TSHR (0.70) | TSHRLMNAALDH1A1ACHETDP1 | |
| SCHEMBL25435523 | 1.00 | TSHR (0.70) | TSHRLMNAALDH1A1ACHETDP1 | |
| Fluoride SCHEMBL6141214 | 0.98 | TSHR (0.67) | TSHRLMNAALDH1A1ACHETDP1 | |
| SCHEMBL27950091 | 0.98 | TSHR (0.67) | TSHRLMNAALDH1A1ACHETDP1 | |
| SCHEMBL19025580 | 0.98 | TSHR (0.67) | TSHRLMNAALDH1A1ACHETDP1 | |
| Ammonia Solution, Strong SCHEMBL27659899 | 0.98 | TSHR (0.67) | TSHRLMNAALDH1A1ACHETDP1 | |
| Bromide SCHEMBL4031266 | 0.98 | TSHR (0.67) | TSHRLMNAALDH1A1ACHETDP1 | |
| Ethane SCHEMBL991925 | 0.96 | TSHR (0.64) | TSHRLMNAALDH1A1ACHETDP1 | |
| Formaldehyde SCHEMBL27686649 | 0.96 | TSHR (0.64) | TSHRLMNAALDH1A1ACHETDP1 | |
| SCHEMBL28053869 | 0.90 | TSHR (0.57) | TSHRLMNAALDH1A1ACHETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4562016-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | Cedilla Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| EP-4539849-A1 | COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 | C4 Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| EP-4519246-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF PRIDOPIDINE | Prilenia Neurotherapeutics Ltd. (IL) | 2025-03-12 | — | — | EP | disclosed |
| WO-2024227104-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BRAF VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| EP-4426289-A1 | AKT3 MODULATORS | Georgiamune Inc. (US) | 2024-09-11 | — | — | EP | disclosed |
| CN-118076593-A | 3CLpro protease inhibitors | 上海齐鲁制药研究中心有限公司 | 2024-05-24 | — | — | CN | disclosed |
| EP-4367113-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | Biogen MA Inc. (US) | 2024-05-15 | — | — | EP | disclosed |
| WO-2024059808-A1 | WEE1 INHIBITORS AND METHODS FOR TREATING CANCER | RECURIUM IP HOLDINGS, LLC (US) | 2024-03-21 | — | — | WO | disclosed |
| WO-2024026483-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| WO-2023244764-A1 | COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 | C4 THERAPEUTICS, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
| WO-2023214412-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATION OF PRIDOPIDINE | PRILENIA NEUROTHERAPEUTICS LTD. (IL) | 2023-11-09 | — | — | WO | disclosed |
| US-11718588-B2 | 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis | GALAPAGOS NV (BE) | 2023-08-08 | — | — | US | disclosed |
| CN-112384517-B | Heteroaryl compounds and uses thereof | 新旭生技股份有限公司 | 2023-07-14 | — | — | CN | disclosed |
| WO-2023081845-A1 | AKT3 MODULATORS | GEORGIAMUNE LLC (US) | 2023-05-11 | — | — | WO | disclosed |
| CN-114929690-B | Novel heterocyclic derivatives having cardiomyocyte proliferative activity for the treatment of heart disease | 同济大学 | 2023-05-05 | — | — | CN | disclosed |
| EP-4146666-A1 | AKT3 MODULATORS | Georgiamune LLC (US) | 2023-03-15 | — | — | EP | disclosed |
| EP-4146185-A1 | AKT3 MODULATORS | Georgiamune LLC (US) | 2023-03-15 | — | — | EP | disclosed |
| WO-2023283610-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | BIOGEN MA INC. (US) | 2023-01-12 | — | — | WO | disclosed |
| CN-114929690-A | Novel heterocyclic derivatives with cardiomyocyte proliferative activity for the treatment of cardiac diseases | 同济大学 | 2022-08-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718588-B2 | 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis | ADAMTS1, ADAMTS5, ADAMTS7 | TSHR 3353/4885LMNA 868/4885ALDH1A1 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.